Teva Pharmaceutical Industries (TEVA) EBITDA (2009 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported EBITDA for 18 consecutive years, with -$231.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, EBITDA fell 150.77% year-over-year to -$231.0 million; the trailing twelve-month figure through Jun 2026 stood at $1.6 billion (up 79.31% YoY), and the FY2025 full-year result was $2.2 billion, up 811.88% from the prior year.
• EBITDA slipped to -$231.0 million in Q2 2026 per TEVA's latest filing, from $652.0 million in the prior quarter.
• Across five years, EBITDA topped out at $882.0 million in Q3 2025 and bottomed at -$967.0 million in Q2 2022.
• Historically, EBITDA has averaged $28.4 million across 5 years, with a median of -$9.0 million in 2023.
• The sharpest annual moves came in 2024 and 2025: EBITDA sank 1576.92% in 2024, then soared 9200.0% in 2025.
• Over 5 years, EBITDA stood at -$940.0 million in 2022, then soared by 180.43% to $756.0 million in 2023, then plunged by 103.84% to -$29.0 million in 2024, then soared by 1134.48% to $300.0 million in 2025, then slumped by 177.0% to -$231.0 million in 2026.
• According to Business Quant data, EBITDA over the past three periods registered -$231.0 million, $652.0 million, and $300.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.